Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.
暂无分享,去创建一个
M. Maris | R. Storb | B. Sandmaier | D. Maloney | B. Storer | F. Appelbaum | M. Pulsipher | R. Maziarz | C. Bredeson | A. Langston | W. Bethge | B. Bruno | F. Petersen | A. Yeager | T. Lange | J. Shizuru | T. Chauncey | B. Gyurkocza | F. Sahebi | E. Agura
[1] H. Döhner,et al. High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.
[2] M. Labopin,et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Haferlach,et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. , 2009, Blood.
[4] Keith Wheatley,et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials , 2009, British journal of haematology.
[5] A. Barrett,et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. , 2009, Blood.
[6] A. Ganser,et al. Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics – Result from An Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem Cell Transplantatioin (SCT). , 2008 .
[7] A. Goldfarb,et al. A Murine Model for the Transient Myeloproliferative Disorder of Down Syndrome: Phenotypic Influence of p53 on Reversible Megakaryoblastic Disorder , 2008 .
[8] J. Sierra,et al. Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) , 2008 .
[9] M. Labopin,et al. Impact of Cytogenetics Risk on Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) from An HLA Identical Sibling for Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1) , 2008 .
[10] T. Naoe,et al. Long-Term Follow-up of the Randomized JALSG AML 201 Study Comparing High Dose Ara-C Therapy with Conventional Consolidation Therapy in Adult Acute Myeloid Leukemia (AML) , 2008 .
[11] J. Melo,et al. Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. , 2008, Blood.
[12] J. Sierra,et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Maris,et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2007, Blood.
[14] J. Ritz,et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] M. Labopin,et al. Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Grou , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Maris,et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Nagler,et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity , 2006, Leukemia.
[18] C. Craddock,et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Ganser,et al. Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML. , 2005 .
[20] T. Zimmerman,et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D. Blaise,et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison , 2005, Leukemia.
[22] J. Radich,et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML , 2005, Leukemia.
[23] H. Deeg,et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Radich,et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] Bob Löwenberg,et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Sorror,et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.
[27] M. Turner,et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[28] A. Ganser,et al. Treatment of Adult Patients with High Risk Acute Myeloblastic Leukemia up to 60 Years: Role of Consolidation Therapy within a Prospective Multicenter Trial. , 2004 .
[29] M. Munsell,et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.
[30] M. Minden,et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison , 2004, Bone Marrow Transplantation.
[31] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] R. Storb,et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.
[33] S. Heimfeld,et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. , 2003, Blood.
[34] R. Storb,et al. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[35] E. Santagostino,et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. , 2003, Blood.
[36] W. Siegert,et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor , 2003, Bone Marrow Transplantation.
[37] R. Storb,et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.
[38] F. Appelbaum,et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. , 2002, Blood.
[39] M. Slovak,et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.
[40] Anajane G. Smith,et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.
[41] F. Appelbaum,et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). , 1998, Blood.
[42] H. Deeg,et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.
[43] O. Garson,et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.
[44] J. Klein,et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. , 1996, Leukemia.
[45] H. Deeg,et al. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. , 1995, Blood.
[46] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[47] H. Deeg,et al. DLA-identical bone marrow grafts after low-dose total body irradiation: the effect of canine recombinant hematopoietic growth factors. , 1994, Blood.
[48] R. Mayer,et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.
[49] J. Gabrilove,et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. , 1991, Blood.
[50] R. Storb,et al. What radiation dose for DLA-identical canine marrow grafts? [published erratum appears in Blood 1989 Feb;73(2):624] , 1988 .
[51] B. Sandmaier,et al. What radiation dose for DLA-identical canine marrow grafts? , 1988, Blood.